Emrosi™ (minocycline hydrochloride extended-release capsules) is now available for the treatment of inflammatory lesions (papules and pustules) of rosacea ...

Journey Medical (DERM) announced the launch of and the first prescriptions filled for Emrosi(TM) (40 mg Minocycline Hydrochloride Modified-Release Capsules, 10 mg immediate release and 30 mg extended ...

The FDA approved minocycline hydrochloride extended-release capsules (Emrosi) for treating inflammatory lesions of rosacea in ...

“The results of these placebo-controlled randomized clinical trials demonstrate that minocycline is efficacious and provides significantly superior outcomes in rosacea compared with placebo and ...

Bhatia emphasized that patient weight and rosacea severity based on inflammatory lesion count do not affect treatment efficacy of sub-antibiotic dosing. “It’s really important not to have that ...

Some people have found success using doxycycline for rosacea. Doxycycline is a tetracycline antibiotic commonly prescribed ...

A study found that DFD-29 was more effective than both doxycycline and placebo, with a favorable risk-benefit profile for ...

Journey Medical has claimed FDA approval for its Emrosi therapy for rosacea, which it thinks could become a "standard of care" drug for the common skin disorder. The new capsule formulation of the ...

If you frequently experience facial redness, irritation and small bumps, you may have rosacea. According to the American Academy of Dermatology, rosacea impacts more than 14 million people in the ...

In the Minocycline Versus Oracea® in Rosacea-1 (MVOR-1) and Minocycline Versus Oracea in Rosacea-2 (MVOR-2) trials, subjects were randomized to receive DFD-29, Oracea, or placebo. The co-primary ...

“As the lowest-dose oral minocycline on the market, Emrosi delivers significantly superior clinical outcomes for rosacea compared to placebo and Oracea® while maintaining a comparable safety profil ...